Kelly Kramer Biography and Net Worth

Director of Gilead Sciences

Ms. Kramer joined our Board in August 2016. Ms. Kramer was Executive Vice President and Chief Financial Officer of Cisco Systems, Inc., a worldwide technology leader, from 2015 until her retirement in 2020. Prior to that, she was Senior Vice President of Corporate Finance at Cisco. She previously served as Vice President and Chief Financial Officer of GE Healthcare Systems and Chief Financial Officer of GE Healthcare Biosciences. Ms. Kramer has also worked in GE’s Corporate Headquarters, Transportation Systems and Aerospace divisions. She currently serves on the board of directors of Snowflake Inc. and Coinbase, Inc.

What is Kelly A. Kramer's net worth?: The estimated net worth of Kelly A. Kramer is at least $164.19 thousand as of November 26th, 2025. Ms. Kramer owns 1,339 shares of Gilead Sciences stock worth more than $164,188 as of December 4th. This net worth approximation does not reflect any other assets that Ms. Kramer may own. Learn More about Kelly A. Kramer's net worth.
How do I contact Kelly A. Kramer?: The corporate mailing address for Ms. Kramer and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Kelly A. Kramer's contact information.
Has Kelly A. Kramer been buying or selling shares of Gilead Sciences?: Over the course of the past ninety days, Kelly A. Kramer has sold $713,186.16 of Gilead Sciences stock. Most recently, Kelly A. Kramer sold 2,805 shares of the business's stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a transaction totalling $356,515.50. Following the completion of the sale, the director now directly owns 1,339 shares of the company's stock, valued at $170,186.90. Learn More on Kelly A. Kramer's trading history.
Who are Gilead Sciences' active insiders?: Gilead Sciences' insider roster includes Gregg Alton (EVP), Jeffrey Bluestone (Director), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), Kelly Kramer (Director), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Daniel O'Day (Chairman and Chief Executive Officer), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Deborah Telman (Executive Vice President, Corporate Affairs and General Counsel), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?: In the last year, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 572,042 shares worth more than $61,902,677.51. The most recent insider tranaction occured on November, 28th when Director Kelly A Kramer sold 2,805 shares worth more than $356,515.50. Insiders at Gilead Sciences own 0.3% of the company. Learn More about insider trades at Gilead Sciences.
Information on this page was last updated on 11/28/2025.

Kelly A. Kramer Insider Trading History at Gilead Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/28/2025	Sell	2,805	$127.10	$356,515.50	1,339
11/26/2025	Sell	2,806	$127.11	$356,670.66	1,339

Kelly A. Kramer Buying and Selling Activity at Gilead Sciences

Gilead Sciences Company Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Today's Range

Now: $122.62

$122.40

$124.96

50 Day Range

MA: $120.76

$110.56

$128.07

2 Week Range

Now: $122.62

$88.57

$128.70

Volume

5,233,233 shs

Average Volume

6,669,524 shs

Market Capitalization

$152.13 billion

P/E Ratio

19.01

Dividend Yield

2.53%

Beta

0.32